AMPK phosphorylates PPARδ to mediate its stabilization, inhibit glucose and glutamine uptake and colon tumor growth

Peroxisome proliferator–activated receptor δ (PPARδ) is a nuclear receptor transcription factor that plays an important role in the regulation of metabolism, inflammation, and cancer. In addition, the nutrient-sensing kinase 5′AMP-activated protein kinase (AMPK) is a critical regulator of cellular energy in coordination with PPARδ. However, the molecular mechanism of the AMPK/PPARδ pathway on cancer progression is still unclear. Here, we found that activated AMPK induced PPARδ-S550 phosphorylation in cancer cells, whereas the PPARδ/S50A (nonphosphorylation mimic) mutant reversed this event. Further analysis showed that the PPARδ/S550E (phosphorylation mimic) but not the PPARδ/S550A mutant increased PPARδ protein stability, which led to reduced p62/SQSTM1-mediated degradation of misfolded PPARδ. Furthermore, PPARδ-S50 phosphorylation decreased PPARδ transcription activity and alleviated PPARδ-mediated uptake of glucose and glutamine in cancer cells. Soft agar and xenograft tumor model analysis showed that the PPARδ/S550E mutant but not the PPARδ/S550A mutant inhibited colon cancer cell proliferation and tumor growth, which was associated with inhibition of Glut1 and SLC1A5 transporter protein expression. These findings reveal a new mechanism of AMPK-induced PPARδ-S550 phosphorylation, accumulation of misfolded PPARδ protein, and inhibition of PPARδ transcription activity contributing to the suppression of colon tumor formation.

5′AMP-activated protein kinase (AMPK) is a serine/threonine kinase, which consists of AMPKα (catalytic subunits) and AMPKβ/AMPKγ (regulatory subunits) (1). Activation of AMPK regulates cell growth, metabolism, autophagy, and cancer progression (2, 3). Under intracellular ATP depletion, AMPK is activated and accelerates catabolism, resulting in ATP production. In addition, AMPK can be activated by the upstream regulatory protein LKB1 in the liver (4). Some pharmacologic reagents such as metformin and 5-aminomidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) can activate AMPK (2, 5, 6). Activation of AMPK triggers the downstream signaling pathways by inducing the targeted proteins FOXO3a or G-alpha-interacting vesicle-associated protein (GIV) phosphorylation leading to autophagy induction (7) and tumor suppression (8). Furthermore, the interaction of AMPK with peroxisome proliferator–activated receptor δ (PPARδ) regulates glucose metabolism, vascular–endothelial dysfunction, insulin resistance, and inflammation (9–12). AMPK interacts with PPARδ leading to increased endurance or training adaptation in mice (9). Omentin-1 inhibits vascular–endothelial dysfunction in response to high glucose, which is associated with inhibition of the AMPK/PPARδ signaling pathway (10). METRN1 alleviates insulin resistance and inflammation in response to lipid or LPS (11, 12), which is involved in activation of AMPK and PPARδ pathways. In addition, PPARδ agonist GW501516-induced glucose uptake of human skeletal muscle cells is AMPK dependent rather than PPARδ (13). As one of the members of PPARs family, PPARδ was the first identified in humans (14), which is highly expressed in colonic epithelial cells and regulates colonic cancer progression (15–20). Ligand-binding and activated PPARδ is involved in the chronic inflammation (ulcerative colitis and Crohn’s disease) and colitis-associated colorectal cancer (CRC) (15–19), suggesting that PPARδ activation enhances CRC. Metformin inhibits PPARδ agonist–mediated colorectal tumorigenesis in azoxymethane/dextran sulfate sodium-induced tumor model (21), whereas the molecular mechanism of this pathway on tumor progression is unclear. Here, we identified that AMPK induced PPARδ-S550 phosphorylation leading to inhibition of its transcription activity and PPARδ-mediated tumor growth.

Results

AMPK induces PPARδ phosphorylation

AMPK can be activated by the agonist metformin (22). SW480 cells treated with metformin induced AMPKα phosphorylation and enhanced the interaction of PPARδ with AMPKα by immunoprecipitation analysis (Fig. 1A). Confocal analysis showed that AMPKα colocalized with PPARδ (Fig. 1B). Further analysis showed that SW480 cells treated with metformin increased PPARδ serine phosphorylation (Fig. 1C). AMPK can induce the substrate phosphorylation...
with the typical LxRxxSxxxL motif (23); alignment analysis by using https://www.ebi.ac.uk/Tools/msa/clustalo/ shows that PPARδ contains this typical motif (Fig. 1D). Glucose starvation can activate AMPK (7). As shown in Figure 1E, the 816.388 m/z at b8 ion fragment was from the parent ion neutral loss of one phosphoric acid (97.972 m/z), suggesting that PPARδ-S50 was phosphorylated in response to glucose starvation. To further analyze AMPK-induced PPARδ-S50

Figure 1. AMPK induces PPARδ phosphorylation. A, SW480 cells were treated with metformin (10 mM) as indicated time. Cell lysates were subjected to immunoprecipitation and Western blot. Input: cell lysates from no metformin treatment. B, SW480 cells were treated with metformin (10 mM) for 3 h. Cells were subjected to confocal analysis. The scar bar represents 20 μm. C, SW480 cells were treated with metformin (10 mM) as indicated time. Cell lysates were subjected to immunoprecipitation and Western blot. D, alignment of the consensus of the PPARδ phosphorylation site with AMPK substrates. E, SW480 cells were treated with or without glucose starvation for 3 h. Cell lysates were subjected to immunoprecipitation. The purified PPARδ protein was identified by LC/MS/MS. F, SW480 cells were transfected with Flag-PPARδ or mutant plasmids for 36 h. After that, cells underwent glucose starvation for 3 h. Cell lysates were subjected to immunoprecipitation and Western blot. G, in vitro kinase assay was performed as described in Experimental procedures. H, SW480 cells were transfected with control shRNA or AMPKα shRNA for 36 h. Cells were treated without or with metformin (10 mM) for 3 h. Cell lysates were subjected to Western blot. AMPK, 5’AMP-activated protein kinase; PPARδ, peroxisome proliferator–activated receptor δ.
phosphorylation, SW480 cells were transfected with PPARδ or PPARδ/S50A mutant and subjected to glucose starvation. As expected, AMPK did not induce PPARδ/S50A mutant phosphorylation (Fig. 1F). AMPK-induced PPARδ-S50 phosphorylation was further demonstrated by in vitro analysis (Fig. 1G). Moreover, AMPKα shRNA-silenced cells inhibited PPARδ-S50 phosphorylation in response to metformin (Fig. 1H). These findings suggest that AMPK induced PPARδ-S50 phosphorylation. Interestingly, activated AMPK induced PPARδ-S50 phosphorylation and increased PPARδ protein levels in response to metformin (Fig. 2A), AICAR, and glucose starvation (Fig. 2, B and C). These findings suggest that AMPK induced PPARδ phosphorylation resulting in accumulation of its protein levels.

**p62/SQSTM1 induces misfolded PPARδ degradation**

Our data showed that AMPK induced PPARδ-S50 phosphorylation, leading to accumulation of PPARδ protein levels, whereas the mechanism is unclear. Further analysis showed that cells treated with the autophagy inhibitor (chloroquine) led to increased PPARδ protein levels (Fig. 3A), suggesting that PPARδ undergoes autophagic degradation. Moreover, metformin-treated cells increased PPARδ half-life (Fig. 3B). Consistently, the half-life of PPARδ/S50E (mimic phosphorylation) was longer than that of PPARδ/S50A (mimic non-phosphorylation) mutant (Fig. 3, C and D), suggesting that AMPK induced PPARδ phosphorylation, resulting in inhibition of PPARδ degradation. Western blot analysis showed that AMPK induced the insoluble PPARδ phosphorylation and inhibited its degradation (Fig. 3E). p62/SQSTM1 was the first identified autophagy receptor, which can induce the misfolded protein autophagic degradation (24, 25). To address whether p62 could mediate PPARδ autophagic degradation, SW480 cells were transfected with p62 shRNA. Half-life analysis showed that silence of p62 increased PPARδ half-life (Fig. 4A). Immunoprecipitation analysis showed that p62 bound to PPARδ (Fig. 4B). However, cells treated with metformin inhibited this event (Fig. 4C). In addition, compared with PPARδ, PPARδ/S50A mutant significantly enhanced the binding of PPARδ to p62, whereas PPARδ/S50E inhibited this event (Fig. 4D). These findings suggest that AMPK induced PPARδ-S50 phosphorylation, leading to inhibition of p62-mediated misfolded PPARδ degradation.

**AMPK/PPARδ pathway inhibits cancer cell metabolism**

As one of the PPARs family members, PPARδ promotes tumor growth (17, 26–29), which is associated with an increase in tumor metabolism (29). To further address whether PPARδ-S50 phosphorylation could affect its transcription activity, the dual-luciferase analysis showed that S50A mutant significantly increased PPARδ activity compared with the WT (PPARδ) (Fig. 5A), and PPARδ agonist GW501516 enhanced this event. However, the S50E mutant reduced PPARδ activity and GW501515 had no effect on PPARδ/S50E activity (Fig. 5A). Immunoprecipitation analysis showed that PPARδ/S50A increased the binding of PPARδ to RXRα (a transcriptional partner of PPARδ) (Fig. 5B). These findings suggest that PPARδ-S50 phosphorylation disrupted the complex of PPARδ/RXRα, leading to inhibition of PPARδ transcription activity. PPARδ can promote the uptake of glucose and glutamine by increasing the expressions of Glut1 and SLC1A5 (29). As expected, compared with PPARδ, PPARδ/S50E mutant significantly inhibited Glut1 and SLC1A5 gene transcription (Fig. 5, C and D), which was in agreement with reduced Glut1 and SLC1A5 protein levels (Fig. 5E). Consistently, PPARδ/S50E significantly inhibited glucose consumption, lactate release, and glutamine uptake (Fig. 5, F–H). These findings suggest that PPARδ-S50 phosphorylation inhibited its transcription activity.

**AMPK/PPARδ inhibits tumor growth**

To further address whether PPARδ-S50 phosphorylation could inhibit cancer cell proliferation and tumor growth, the soft agar analysis and xenograft mouse model were performed. Compared with PPARδ, PPARδ/S50A markedly enhanced cancer cell proliferation and tumor growth, whereas PPARδ/S50E mutant inhibited this event (Fig. 6, A–C), which was associated with the inhibition of Glut1 and SLC1A5 expressions in S50E-expressed tumors (Fig. 6D). These findings suggest that AMPK induced PPARδ-S50 phosphorylation leading to inhibition of PPARδ-mediated tumor growth.

**Discussion**

PPARs contain PPARα, PPARγ, and PPARδ (30–34). PPARδ can be activated by the fatty acids or fatty-acid derivatives, which is involved in the mucosal inflammation and malignant transformation (26). Aberrant PPARδ expression or activation can cause metastatic progression and carcinogenesis of CRC (15, 16, 26, 29, 35). Consistently, PPARδ KO reduces colon inflammation and colitis-associated tumor growth (17). Conversely, clinical observation shows that higher expression of PPARδ increases survival in patients with CRC (36, 37). Overexpression of PPARδ or activation by agonists decreases CRC cell proliferation and colorectal tumorigenesis (37–40). In contrast, silence or KO of PPARδ promotes colon cancer cell proliferation and tumor growth (41–43). These discrepancy findings could be derived from different models and ligand specificity. AMPK is the metabolic sensor that regulates cellular and organismal metabolism in eukaryotes, which is activated in response to intracellular ATP depletion (2, 22). AMPK plays a critical role in regulating cell growth and metabolism (2). However, the effect of AMPK on PPARδ-mediated cancer cell metabolism and tumor growth is unclear. AMPK induces G1/S phosphorylation, leading to stabilization of epithelial tight junctions and inhibition of tumorigenesis (8), suggesting that AMPK can act as a tumor suppressor. Although the AMPK/PPARδ pathway can regulate glucose and lipid metabolism (9, 13, 44–46), the mechanism of this interaction is unclear. Here, we identified that PPARδ contains the typical motif of AMPK phosphorylation substrate (LxRxS/S50) xxxL, which was further demonstrated by LC/MS/MS and in vitro kinase assay. AMPK induced misfolded PPARδ-S50
Figure 2. AMPK induces PPARδ-S50 phosphorylation, resulting in accumulation of PPARδ protein levels. A, cells were treated with metformin (10 mM) at the indicated time. Cell lysates were subjected to Western blot. The relative PPARδ protein levels were quantified. Results are expressed as the means ± SEM (n = 3). *p < 0.05. B, SW480 cells were treated with 5 mM AICAR at the indicated time. Cell lysates were subjected to Western blot. C, Western blot analysis of SW480 cell lysates in response to glucose starvation. AICAR, 5-aminimidazole-4-carboxamide-1-β-d-ribofuranoside; AMPK, 5′AMP-activated protein kinase; PPARδ, peroxisome proliferator–activated receptor δ.
phosphorylation, leading to inhibition of p62-mediated misfolded PPARδ autophagic degradation. Other reports suggest that KRAS could regulate autophagy (47, 48), and SW480 and HCT-116 are KRAS mutant colon cancer cells, whereas the increased PPARδ protein levels were similar to KRAS WT (CW-2, HT-29) colon cancer cells (Fig. 2A). Protein quality control plays an important role in refolding and degrading misfolded proteins (49–51). Enhanced degradation of misfolded proteins promotes tumorogenesis (52), and cancer cell exhibits the capacity to remove misfolded protein (53). In contrast, the accumulation of misfolded protein is associated with tumor suppression (52, 53). PPARδ-S50 phosphorylation inhibited PPARδ transcription activity, metabolic pathway, and tumor growth, suggesting that AMPK acts as tumor suppressor in cancer cells by inducing PPARδ phosphorylation. Consistently, AMPK induces the downstream GIV phosphorylation leading to tumor suppression (8). Activated PPARδ binds to the peroxisome-proliferator response element (PPRE) consensus sequence (AGGTCA/NAGGTCA) in the promoter of the target genes and triggers the gene expressions (30–33). Glut1 and SLC1A5 are the direct targets of PPARδ (29), while AMPK induced PPARδ-S50 phosphorylation leading to inhibition of this event, suggesting that PPARδ-S50 phosphorylation suppressed PPARδ-mediated glucose and glutamine metabolic pathways. Glucose metabolism is required for biosynthesis of macromolecules in most types of cancer cells (54). In this process, Glut1 plays a critical role in glucose uptake to maintain cancer cell growth and proliferation (55, 56). In addition, SLC1A5 serves as an important regulator of essential amino acid influx (57). Depletion or silence of SLC1A5 terminates tumor progression (29, 58). Consistent with this, our results showed that AMPK-induced PPARδ-S50 phosphorylation abolished PPARδ transcription activity and reduced uptake of glucose and glutamine and, subsequently, decreased cancer cell proliferation and xenograft tumor growth. Taken together, AMPK induced PPARδ-S50 phosphorylation and reduced PPARδ transcription activity, leading to inhibition of PPARδ-mediated metabolic pathway and tumor growth (Fig. 7).

**Experimental procedures**

**Cells, reagents, and plasmids**

The human SW480, HCT-116, HT-29, and CW-2 colon cancer cell lines were obtained from the ATCC and maintained in 10% fetal bovine serum (FBS, Gibco) Dulbecco’s modified Eagle’s medium (DMEM). PPRE3-I luc plasmid was described previously (31). Human PPARδ cDNA was cloned into the pcDNA3 vector, PPARδ/S50A, or PPARδ/S50E was mutated by the site-directed mutagenesis method and identified by DNA sequencing. The mutant primers: S50A forward: CCCGAGCTCCGGCCACCACCTCCTACAT; S50A reverse: AGTGAGGTTGGCCGGAGCTCCTCGG. S50E forward: CCCGGAGCTCCTCGAGCCACCCTCCTACAT; S50E reverse: AGTGAGGTTGGCCGGAGCTCCTCGG.
reverse: AGTGAGGGTGGCTCGGAGCTCCGGG. p62 and AMPKα shRNA plasmids were purchased from GeneChem. Plasmids were transfected into cells by using the TurboFect Transfection Reagent (Thermo Fisher Scientific). AICAR and protease inhibitor cocktail were obtained from Sigma. Metformin was purchased from Bomei biotech. Geneticin (G418 sulfate) was obtained from Thermo Fisher Scientific. Antibodies and Western blot

PPARδ (Cat: SC-74440) was obtained from Santa Cruz. GAPDH (Cat: 60004) was obtained from Proteintech. p62 (Cat: ab56416) was obtained from Abcam. Actin (Cat: D195316), GST (Cat: D110271), and Flag (Cat: D110005) were purchased from Sangon Biotech. AMPKα (RLT026), phospho-AMPKα1/2 (RLP0575), and anti-phosphoserine (RLM3440) were purchased from Ruiying Biological. The p-PPARδ-S50 mouse polyclonal antibody was developed by using human PPARδ peptide PSSYTDLSRSSpPPSLLDQL (nonphosphorylation peptide as a negative control), which was purchased from Chinese Peptide Company. Western blot analysis showed that the p-PPARδ-S50 antibody did not cross-react with other PPAR family members (Fig. S1). Secondary antibodies were obtained from Jackson.

**Figure 4. PPARδ-S50 phosphorylation inhibits p62-mediated misfolded PPARδ degradation.** A, the half-life of PPARδ was assayed in p62 shRNA-silenced SW480 cells. The relative PPARδ protein remaining at each time point was calculated. Results are expressed as the means ± SEM (n = 3). *p < 0.01. B, cell lysates of SW480 cells were subjected to immunoprecipitation and Western blot. C, SW480 cells were transfected with the vector or PEBG-PPARδ for 36 h. Cells were treated with metformin (10 mM) for 1 h as indicated. Cell lysates were subjected to immunoprecipitation and Western blot. D, SW480 cells were transfected with Flag-PPARδ or mutant plasmids as indicated for 36 h. Cell lysates were subjected to immunoprecipitation and Western blot. PPARδ, peroxisome proliferator–activated receptor δ.
ImmunoResearch. Cells were lysed in the lysis buffer (50 mM Tris HCl, pH 7.4, 250 mM NaCl, 0.5% Triton X-100, PMSF, 10% glycerol, protease inhibitor cocktail). Protein concentration was determined by using the Pierce BCA Protein Assay Kit (Thermo). The samples were subjected to SDS-PAGE, transferred to a nitrocellulose membrane, and then probed by the indicated antibodies and developed by using an ECL reagent. Blots were quantified by using ImageJ.

Immunoprecipitation and GST pull-down assay

For immunoprecipitation, cell lysates were precleared with protein A/G PLUS-agarose (Cat: sc-2003, Santa Cruz). Precleared lysates with protein A/G PLUS-agarose beads were added with indicated primary antibodies for 1 h. After that, 15-μl protein A/G PLUS-agarose beads were added and rocked overnight at 4 °C. The beads were washed with ice-cold PBS and subsequently subjected to Western blot with indicated antibodies. For GST pull-down analysis, 15-μl MagBeads GST Fusion Protein Purification (C650031, Sangon Biotech Shanghai) was added to cell lysates and rocked overnight at 4 °C. After that, beads were washed with ice-cold PBS. The samples were subjected to Western blot with the indicated antibodies.

Soluble and insoluble protein fractionation analysis

Cells were incubated with the lysis buffer (50 mM Tris HCl, pH 7.6, 150 mM NaCl, 1% Triton X-100, 30 mM NaN, 1 mM EDTA, protein inhibitors) on ice for 20 min. The lysates were centrifuged at 500,000g for 2 min at 4 °C. The supernatants were further centrifuged at 20,000g for 20 min at 4 °C. The supernatants and pellets were collected as detergent-soluble and -insoluble fractions. Insoluble fractions were sonicated. Fractions were subjected to 7% SDS-PAGE and Western blot.

L-glutamine uptake analysis

L-glutamine uptake analysis was described previously (29). After amino acid starvation by FBS deprivation for 20 h, SW480 cells (1 × 10^4) were incubated with D-PBS buffer (20 mM Hepes and 1 g/l D-glucose, CaCl2, MgCl2) for 3 h. After that, cells were cultured in MEM containing 4 mM L-glutamine for 45 min. Cells were washed with PBS, and intracellular glutamine levels were measured using the L-Glutamine Assay kit (Goybio) and normalized to total protein levels.

Glucose consumption and lactate release assay

The glucose consumption and lactate release assay were described previously (29). SW480 cells (1 × 10^4) were grown in DMEM (5.5 mmol/l glucose) with 10% FBS. After cell...
confluence, the medium was discarded, and then, the same FBS/DMEM was added for 12 h. The medium was collected for glucose consumption and lactate release assay. The glucose concentrations were assayed by using the assay kit (Applygen). Lactate release was assayed by colorimetric assay kit (Goybio). The cell number was determined by trypan blue exclusion assay for normalization.

**In vitro kinase assay**

PPARδ cDNA was subcloned into the PGEX-6P-1 vector. The GST-PPARδ or S50A mutant was expressed in *Escherichia coli* strain BL21. The recombinant protein was purified by glutathione-conjugated Sepharose beads. 50 ng purified AMPKα heterotrimer (Signal Chem), GST-PPARδ, or GST-PPARδ-S50A (10 ng) was added in the reaction buffer (20 mM Hepes, pH 7.4, 10 mM MgCl₂, 1 mM EGTA, 10 mM ATP, 1 mM DTT) for 40 min at 30 °C. The reactions were subjected to Western blot with indicated antibodies.

**MS assay**

SW480 cells were treated with or without glucose starvation for 3 h. Cell lysates were subjected to immunoprecipitation by using the PPARδ antibody. Samples with the loading buffer were boiled and then subjected to SDS-PAGE. The gel-purified phosphorylated and unphosphorylated PPARδ proteins were digested with chymotrypsin and trypsin. The digested peptides were assayed by using UPLC-Q-Exactive (Thermo Fisher) at Aixiang Biotech Company in China. Peptide coverage is 78.23% of PPARδ amino acid sequence. The data were searched against UniProt database, and the peptide false discovery rate was <1%.

**Immunofluorescent analysis**

SW480 cells were treated with metformin (10 mM) for 1 h. Cells were fixed (3.7% paraformaldehyde), permeabilized (0.5% Triton X-100), blocked (10% BSA), and then incubated with the indicated primary antibodies and secondary antibodies (Jackson ImmunoResearch). Immunostained cells were viewed in a confocal microscope.

**Luciferase assay**

For the PPARδ transcription activity assay, cells were transfected with PPRE₃-lu and Ptk-RL together with PPARδ or mutant plasmids for 36 h. Cells were treated with GW501516 as indicated for another 12 h. For the Glut1 or SLC1A5 transcription activity analysis, cells were transfected with Glut1-lu or SLC1A5-lu together with Ptk-RL, PPARδ, or mutant plasmids as indicated for 36 h. Cell lysates were assayed by using a dual-luciferase reporter assay system (Promega).

**Soft agar analysis**

SW480 cells were transfected with PPARδ or mutant (S50A, S50E) plasmids. Cells were selected with G418 to develop
stable gene-expressing cell lines. Cells ($3 \times 10^3$) were sus-
pended in 0.35% noble agar with 10% FBS DMEM and were
layered over 0.5% agar in six-well plates. A normal culture
medium with 500 $\mu$g/ml G418 was added to each well. After
2 weeks, dishes were stained with 0.05% crystal violet, and
colonies were counted.

**Xenograft mouse model**

Eight-week-old female NU/NU nude mice were purchased
from the laboratory animal center of Yangzhou University.
Stable PPAR$\delta$, S50A, or S50E expressing SW480 cells ($1 \times 10^6$
) by using G418 selection were injected subcutaneously in nude
mice. Each group contains five mice. After 4 weeks, the tumor
volume was measured. Tumor volume $= \frac{1}{2} (\text{length} \times \text{width}^2)$.
All studies were carried out with the approval of the Jiangsu
University Animal Care Committee.

**Statistical analysis**

Data are expressed as the mean $\pm$ SEM. Differences between
two dependent groups were evaluated with the paired Student’s $t$
test.

**Data availability**

Additional data are available as Supplementary information.

**Supporting information**—This article contains supporting
information.

**Acknowledgments**—This work was supported by the National Nat-
ural Science Foundation of China (81972618, 81672711, 81872275),
Jiangsu Commission of Health, Natural Science Foundation
(M20200002), and Changzhou Sci & Tech Program (Grant No.
CJ20200004).

**Author contributions**—J. D., Q. G., X. J., and Q. L. investigation; J. J.
and J. S. methodology; J. J. and J. S. writing—original draft; J. J., J. S.,
and Y. H. writing—review and editing; J. S. and Y. H. supervision; Y.
H. conceptualization; Y. H. project administration.

**Conflict of interest**—The authors declare that they have no conflicts
of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: AICAR, 5-
aminoimidazole-4-carboxamide-1-$\beta$-d-ribofuranoside; AMPK,
5’AMP-activated protein kinase; CRC, colorectal cancer; FBS, fetal
bovine serum; GIV, G-alpha-interacting vesicle-associated protein;
PPAR$\delta$, peroxisome proliferator–activated receptor $\delta$; PPRE,
peroxisome proliferator response element.

**References**

1. Lage, R., Dieguez, C., Vidal-Puig, A., and Lopez, M. (2008) AMPK: A
metabolic gauge regulating whole-body energy homeostasis. Trends Mol.
Med. 14, 539–549
2. Mihaylova, M. M., and Shaw, R. J. (2011) The AMPK signalling pathway
coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13,
1016–1023
3. Hardie, D. G. (2015) Molecular pathways: Is AMPK a friend or a foe in
cancer? Clin. Cancer Res. 21, 3836–3840
4. Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., Depinho,
R. A., Montminy, M., and Cantley, L. C. (2005) The kinase LKB1 mediates
glucose homeostasis in liver and therapeutic effects of metformin. Science
310, 1642–1646
AMPK/PPARδ pathway

5. Hardie, D. G., Ross, F. A., and Hawley, S. A. (2012) AMPK: A nutrient and energy sensor that regulates energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251–262

6. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Deoebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174

7. Shin, H. J., Kim, H., Oh, S., Lee, J. G., Kee, M., Ko, H. J., Kweon, M. N., Won, K. J., and Baek, S. H. (2016) AMPK-SKP2-CARM1 signalling cascade in transcriptional regulation of autophagy. Nature 534, 553–557

8. Aznar, N., Patel, A., Rohena, C. C., Dunkel, Y., Joosen, L. P., Taupin, V., Kufareva, I., Farquhar, M. G., and Ghosh, P. (2016) AMP-activated protein kinase fortifies epithelial tight junctions during energetic stress via its effector GIV/Girdin. Elife 5, e20795

9. Narkar, V. A., Downes, M., Yu, R. T., Embler, E., Wang, Y. X., Banayo, E., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L., and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174

10. Hou, Y., Gao, J., Jin, J., and Hou, Y. (2018) PPARalpha enhances cancer cell invasion and enhances metastasis. Oncogene 37, 5619–5625

11. Gupta, R. A., Wang, D., Karthik, S., Wang, H., Dey, S. K., and Dey, S. K. (2008) Peroxisome proliferator-activated receptor-beta/delta expression in colon cancer. Cancer Res. 68, 907–917

12. Williams, J. L., Kramer, L. R., Clapper, M. L., Gonzalez, F. J., and Peters, J. M. (2006) Ligand activation of peroxisome proliferator-activated receptor-beta/delta expression in colon cancer. Mol. Cancer Res. 4, 106–114

13. Michalik, L., Desvergne, B., and Wahli, W. (2004) Peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 101, 7650–7655

14. Yang, L., Zhang, H., Zhou, Z. G., Yan, H., Adell, G., and Sun, X. F. (2011) PPARalpha activation induces p-AKT signaling and suppresses p-ERK and represses p-AMPK signaling. Mol. Pharmacol. 80, 405–415

15. Michalik, L., Desvergne, B., and Wahli, W. (2004) Peroxisome proliferator-activated receptor-beta/delta expression in colon cancer. Mol. Cancer Res. 4, 106–114

16. Narkar, V. A., Downes, M., Yu, R. T., Embler, E., Wang, Y. X., Banayo, E., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L., and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174

17. Hou, Y., Gao, J., Jin, J., and Hou, Y. (2018) PPARalpha enhances cancer cell invasion and enhances metastasis. Oncogene 37, 5619–5625

18. Williams, J. L., Kramer, L. R., Clapper, M. L., Gonzalez, F. J., and Peters, J. M. (2006) Ligand activation of peroxisome proliferator-activated receptor-beta/delta expression in colon cancer. Mol. Cancer Res. 4, 106–114

19. Yang, L., Zhang, H., Zhou, Z. G., Yan, H., Adell, G., and Sun, X. F. (2011) PPARalpha activation induces p-AKT signaling and suppresses p-ERK and represses p-AMPK signaling. Mol. Pharmacol. 80, 405–415

20. Narkar, V. A., Downes, M., Yu, R. T., Embler, E., Wang, Y. X., Banayo, E., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L., and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174

21. Hou, Y., Gao, J., Jin, J., and Hou, Y. (2018) PPARalpha enhances cancer cell invasion and enhances metastasis. Oncogene 37, 5619–5625

22. Williams, J. L., Kramer, L. R., Clapper, M. L., Gonzalez, F. J., and Peters, J. M. (2006) Ligand activation of peroxisome proliferator-activated receptor-beta/delta expression in colon cancer. Mol. Cancer Res. 4, 106–114

23. Michalik, L., Desvergne, B., and Wahli, W. (2004) Peroxisome proliferator-activated receptor-beta/delta expression in colon cancer. Mol. Cancer Res. 4, 106–114
41. Yang, L., Zhou, Z. G., Zheng, X. L., Wang, L., Yu, Y. Y., Zhou, B., Gu, J.,
and Li, Y. (2008) RNA interference against peroxisome proliferator-
activated receptor delta gene promotes proliferation of human colorec-
tal cancer cells. *Dis. Colon Rectum* **51**, 318–326. discussion 326–318

42. Yang, L., Zhou, J., Ma, Q., Wang, C., Chen, K., Meng, W., Yu, Y., Zhou,
and Sun, X. (2013) Knockdown of PPAR delta gene promotes the
growth of colon cancer and reduces the sensitivity to bevacizumab in
nude mice model. *PLoS One* **8**, e60715

43. Yang, L., Olsson, B., Pfeifer, D., Jonsson, J. I., Zhou, Z. G., Jiang, X.,
Fredriksson, B. A., Zhang, H., and Sun, X. F. (2010) Knockdown of
peroxisome proliferator-activated receptor-beta induces less differentia-
tion and enhances cell-fibronectin adhesion of colon cancer cells.
*Oncogene* **29**, 516–526

44. Cheang, W. S., Wong, W. T., Zhao, L., Xu, J., Wang, L., Lau, C. W., Chen,
Z. Y., Ma, R. C., Xu, A., Wang, N., Tian, X. Y., and Huang, Y. (2017)
PPARdelta is required for exercise to attenuate endoplasmic reticulum
stress and endothelial dysfunction in diabetic mice. *Diabetes* **66**, 519–528

45. Bojic, L. A., Telford, D. E., Fullerton, M. D., Ford, R. J., Sutherland, B. G.,
Edwards, J. Y., Sawyez, C. G., Gros, R., Kemp, B. E., Steinberg, G. R., and
Huff, M. W. (2014) PPARdelta activation attenuates hepatic steatosis in
Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and
improved insulin sensitivity. *J. Lipid Res.* **55**, 1254–1266

46. Choy, K. W., Mustafa, M. R., Lau, Y. S., Liu, J., Murugan, D., Lau, C. W.,
Wang, L., Zhao, L., and Huang, Y. (2016) Paeonol protects against
endoplasmic reticulum stress-induced endothelial dysfunction via
AMPK/PPARdelta signaling pathway. *Biochem. Pharmacol.* **116**, 51–62

47. Lo Re, A. E., Fernandez-Barrena, M. G., Almada, L. L., Mills, L. D.,
Elswa, S. F., Lund, G., Kropol, A., Molejon, M. I., Vaccaro, M. I., and
Fernandez-Zapico, M. E. (2012) Novel AKT1-GLI3-VMP1 pathway
mediates KRAS oncogene-induced autophagy in cancer cells. *J. Biol.
Chem.* **287**, 25325–25334

48. Jiffry, J., Thavornwatanayong, T., Rao, D., Fogel, E. J., Saytoo, D., Nahata,
R., Guzik, H., Chaudhary, I., Augustine, T., Goel, S., and Maitra, R. (2021)
Oncolytic reovirus (pelareorep) induces autophagy in KRAS-mutated
colorectal cancer. *Clin. Cancer Res.* **27**, 865–876

49. Balch, W. E., Morimoto, R. I., Dillin, A., and Kelly, J. W. (2008) Adapting
proteostasis for disease intervention. *Science* **319**, 916–919

50. Kaur, J., and Debnath, J. (2015) Autophagy at the crossroads of catabolism
and anabolism. *Nat. Rev. Mol. Cell Biol.* **16**, 461–472

51. Kim, Y. E., Hipp, M. S., Bracher, A., Hayer-Hartl, M., and Hartl, F. U.
(2013) Molecular chaperone functions in protein folding and proteostasis.
*Annu. Rev. Biochem.* **82**, 323–355

52. Chen, L., Brewer, M. D., Guo, L., Wang, R., Jiang, P., and Yang, X. (2017)
Enhanced degradation of misfolded proteins promotes tumorigenesis.
*Cell Rep.* **18**, 3143–3154

53. Tang, Z., Dai, S., He, Y., Doty, R. A., Shultz, L. D., Sampson, S. B., and
Dai, C. (2015) MEK guards proteome stability and inhibits tumor-
suppressive amyloidogenesis via HSF1. *Cell* **160**, 729–744

54. Boroughs, L. K., and DeBerardinis, R. J. (2015) Metabolic pathways
promoting cancer cell survival and growth. *Nat. Cell Biol.* **17**, 351–359

55. Zhao, F. Q., and Keating, A. F. (2007) Functional properties and genomics
of glucose transporters. *Curr. Genomics* **8**, 113–128

56. Young, C. D., Lewis, A. S., Rudolph, M. C., Ruehl, M. D., Jackman, M. R.,
Yun, U. J., Ilkun, O., Pereira, R., Abel, E. D., and Anderson, S. M. (2011)
Modulation of glucose transporter 1 (GLUT1) expression levels alters
mouse mammary tumor cell growth *in vitro* and *in vivo*. *PLoS One* **6**, e23205

57. Nicklin, P., Bergman, P., Zhang, B., Triantafelllow, E., Wang, H., Nyfeler, B.,
Yang, H., Hild, M., Kung, C., Wilson, C., Myer, V. E., MacKeigan, J. P.,
Porter, J. A., Wang, Y. K., Cantley, L. C., *et al.* (2009) Bidirectional transport
of amino acids regulates mTOR and autophagy. *Cell* **136**, 521–534

58. Jeon, Y. J., Khelifa, S., Ratnikov, B., Scott, D. A., Feng, Y., Parisi, F., Ruller,
C., Lau, E., Kim, H., Brill, L. M., Jiang, T., Rimm, D. L., Cardiff, R. D.,
Mills, G. B., Smith, J. W., *et al.* (2015) Regulation of glutamine carrier
proteins by RNFL5 determines breast cancer response to ER stress-
inducing chemotherapies. *Cancer Cell* **27**, 354–369